Ubs Asset Management Americas Inc Entrada Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 35,750 shares of TRDA stock, worth $466,179. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,750
Previous 14,156
152.54%
Holding current value
$466,179
Previous $226,000
173.45%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TRDA
# of Institutions
104Shares Held
28.9MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$63.5 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$57.5 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$57.1 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$37.9 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$27.1 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $409M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...